Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (76)	9/2/2003 9:05:28 PM
From: SemiBull	Read Replies (1) \| Respond to of 671

siRNA, Oligo-Based Therapeutics, Intellectual Property & Investment Outlook To Feature at Sept 15-17, 2003 Boston Nucleic Acid Conference Tuesday September 2, 8:04 am ET BOSTON, Sept. 2 /PRNewswire/ -- The Annual "Nucleic Acid World Summit" (NAWS) conference is organized into three concurrent tracks and as of today, will be attended by over 225 delegates September 15-17, 2003 in Boston, MA, announces Strategic Research Institute. The two and a half day conference and exposition will feature topics such as small-interfering RNA in drug discovery, siRNA/RNAi target validation, Oligo-based therapeutics: pre-clinical and clinical development, nucleic acid delivery, aptamers, antisense, ribozymes, locked nucleic acid, RNA trans-splicing, oligos, investment outlook, partnering opportunities, and more. The conference will feature over 65 speakers represented by over 60 different companies. To request a copy of the agenda in PDF format, please contact Glenn Pascual at gpascual@srinstitute.com or call 212-967-0095, x245 and include mailing address with full contact information. To inquire about sponsorship & exhibition opportunities, please contact Kellie Swanstrom at kswanstrom@srinstitute.com or call 973.571.0867. Companies sponsoring and exhibiting at the event include Aventis Oncology, Sirna Therapeutics, Ambion, Avatar Pharmaceutical Services, BD Biosciences Clontech, CSIRO, Dharmacon, Qiagen Inc., Xenogen, Archemix, Combimatrix, Promega Biosciences, Provita Biotherapeutics, International Therapeutics, Elchrom Scientific, University of Massachusetts Medical School, and Dow Chemical Company. To inquire on how to become a media partner, please contact Cheryl-Kahan Radhuber at ckahan-radhuber@srinstitute.com or call 212-967-0095, ext.273 Source: Strategic Research Institute

To: tuck who wrote (76)	9/9/2003 10:19:02 AM
From: keokalani'nui	Read Replies (2) \| Respond to of 671

Merck forms pact with biotech on new genetic method Tuesday September 9, 8:28 am ET NEW YORK, Sept 9 (Reuters) - Merck & Co. Inc. (NYSE:MRK - News), a drugmaker known for being on the cutting edge of research, on Tuesday said it had formed the first alliance between a large pharmaceutical company and a biotech over new technology known as RNA interference. The deal, with privately held Alnylam Holding Co., will investigate new therapies using the technology, which is designed to block messages the body send for certain disease-causing genes.